PBZ-SR
LOE ApproachingNDAORALTABLET, EXTENDED RELEASE
Approved
Jul 1956
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 14h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PBZ-SR is an oral extended-release small molecule tablet approved by Novartis in 1956. The mechanism of action and specific indications are not publicly detailed in available data. This is a legacy product nearing loss of exclusivity.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), brand teams are likely in maintenance/transition mode with limited growth investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring for PBZ-SR; this is a legacy asset with a small, stable team. Career roles are typically maintenance-focused, managing decline and protecting remaining market share against generics.
Brand ManagerField Sales Representative
Worked on PBZ-SR at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.